Where Does Wall Street Think ZIOPHARM Oncology Inc. (ZIOP) Stock Will Go?

Friday, January 07, 2022 10:55 AM | InvestorsObserver Analysts

Mentioned in this article

Where Does Wall Street Think ZIOPHARM Oncology Inc. (ZIOP) Stock Will Go?

Analysts who follow ZIOPHARM Oncology Inc. (ZIOP) on average expect it to gain 216.60% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns ZIOPHARM Oncology Inc. an Analyst Ranking of 15, which means it ranks higher than 15 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating ZIOP a Buy today. Find out what this means to you and get the rest of the rankings on ZIOP!

See Full ZIOP Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With ZIOPHARM Oncology Inc. Stock Today?

ZIOPHARM Oncology Inc. (ZIOP) stock is trading at $1.00 as of 10:55 AM on Friday, Jan 7, a loss of -$0.02, or -1.96% from the previous closing price of $1.02. The stock has traded between $1.00 and $1.05 so far today. Volume today is below average. So far 139,989 shares have traded compared to average volume of 2,667,360 shares. Click Here to get the full Stock Report for ZIOPHARM Oncology Inc. stock.